CLDN5 and diabetic retinopathy: VME treatment reduced specific indicators of diabetic retinopathy, such as the degradation of OCLN (occludin), ZO-1 (zonula occludens-1), CLDN5 (claudin-5), and VEGF (retinal vascular endothelial growth factor) expression in diabetic rats.